Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice.

表达 RBD 的腺病毒纳米颗粒可诱导小鼠产生针对 BA.5 的保护性免疫反应

阅读:9
作者:Mo Chuncong, Wang Zhongfang, Liu Donglan, Yang Xiaoyun, Zhang Qiong, Ye Lihua, Yuan Shuai, Deng ShiDong, Lai Zhulan, Huang Deyi, Yang Yujie, Xu Duo, Yuan Jinwei, Zhu Yuhui, Liu Haoyi, Zhou Chengxing, Liao Xiaohong, Li Xiao, Liu Wenkuan, Zhou Rong, Tian Xingui
INTRODUCTION: Adenovirus (Ad) vectors demonstrated significant efficacy as vaccine vectors during the COVID-19 pandemic. Hexon is the major capsid protein, and multiple hypervariable regions (HVRs) have been used for displaying exogenous antigens and inducing a strong antibody responses. METHODS: We utilized SpyCatcher/SpyTag technology to incorporate SpyTag into HVR2, 4, and 7 of the hexon of the bivalent vaccine strain rAd3/7, respectively, to construct recombinant Ad, rAd3/7-SpyTag. The receptor-binding domain (RBD) of the SARS-CoV-2 BA5.2 strain fused with SpyCatcher was expressed as SpyCatcher-RBD, Spycatcher-RBD and rAd3/7-SpyTag were incubated in vitro to prepare a novel nanoparticle vaccine candidate, rAd3/7-SpyRBD, against SARS-CoV-2. Characterize rAd3/7-SpyRBD using Western blot, ELISA, transmission electron microscopy (TEM), and particle size measurement, and verify its immunogenicity through mouse immunization. RESULTS: We have successfully established a universal nanoparticle vaccine platform, rAd3/7-SpyTag, and the RBD protein was successfully displayed on the surface of rAd3/7-SpyTag. Compared with SpyCatcher-RBD, rAd3/7-SpyRBD can rapidly induce the production of antibodies and stronger immune responses. Both Spycatcher-RBD and rAd3/7-SpyRBD provide a protective immune response against BA.5 in mouse model mice and can be used as candidates for SARS-CoV-2 vaccine. We also found that rAd3/7-SpyRBD induced the production of neutralizing antibodies against Ad3 and Ad7, suggested that it could serve as an Ads vaccine candidate. CONCLUSION: We developed a universal nanoparticle vaccine platform and obtained a trivalent vaccine candidate rAd3/7-SpyRBD, against SARS-CoV-2, Ad3, and Ad7, and this is the first time to use SpyCatcher/SpyTag technology in a bivalent rAd3/7 vector for trivalent immunity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。